BR9509172A - Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica - Google Patents
Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéuticaInfo
- Publication number
- BR9509172A BR9509172A BR9509172A BR9509172A BR9509172A BR 9509172 A BR9509172 A BR 9509172A BR 9509172 A BR9509172 A BR 9509172A BR 9509172 A BR9509172 A BR 9509172A BR 9509172 A BR9509172 A BR 9509172A
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- complement pathway
- pathway protein
- mammal
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9418147A GB9418147D0 (en) | 1994-09-08 | 1994-09-08 | Modified proteins |
| GBGB9509102.1A GB9509102D0 (en) | 1995-05-04 | 1995-05-04 | Modified proteins |
| PCT/GB1995/002121 WO1996007738A2 (en) | 1994-09-08 | 1995-09-08 | Modified human c3 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9509172A true BR9509172A (pt) | 1997-11-25 |
Family
ID=26305590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9509172A BR9509172A (pt) | 1994-09-08 | 1995-09-08 | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5849297A (pt) |
| EP (1) | EP0779922B1 (pt) |
| JP (1) | JPH10505241A (pt) |
| CN (1) | CN1104501C (pt) |
| AT (1) | ATE273388T1 (pt) |
| AU (1) | AU707004B2 (pt) |
| BG (1) | BG63606B1 (pt) |
| BR (1) | BR9509172A (pt) |
| CA (1) | CA2197888A1 (pt) |
| CZ (1) | CZ290596B6 (pt) |
| DE (1) | DE69533359T2 (pt) |
| ES (1) | ES2224133T3 (pt) |
| FI (1) | FI970979A0 (pt) |
| HU (1) | HUT77874A (pt) |
| NO (1) | NO971059L (pt) |
| NZ (2) | NZ333949A (pt) |
| PL (1) | PL319040A1 (pt) |
| RO (1) | RO117189B1 (pt) |
| RU (1) | RU2194713C2 (pt) |
| SK (1) | SK29697A3 (pt) |
| WO (1) | WO1996007738A2 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK121798A3 (en) | 1996-03-07 | 1999-04-13 | Imutran Ltd | Native protein of a complement line, a fragment or variant of protein, dna sequence coding a protein, dna construct, a conjugate containing protein, pharmaceutical composition and use of protein |
| WO1998039659A1 (en) * | 1997-03-06 | 1998-09-11 | Bion Diagnostic Sciences, Inc. | Screening and treatment using complement regulator or receptor proteins |
| US6221621B1 (en) | 1997-03-06 | 2001-04-24 | Bard Diagnostic Sciences, Inc. | Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated |
| WO2001092295A2 (en) * | 2000-05-30 | 2001-12-06 | University Of Toronto | Ligands for cd21 and compositions thereof for modulating immune responses |
| US7294688B2 (en) * | 2001-04-30 | 2007-11-13 | Nanogen Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons |
| US6756476B2 (en) * | 2001-04-30 | 2004-06-29 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons |
| US6998243B2 (en) * | 2001-04-30 | 2006-02-14 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons |
| US7314717B2 (en) * | 2001-04-30 | 2008-01-01 | Nanogen Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons |
| US7179610B2 (en) * | 2001-11-23 | 2007-02-20 | Nanogen Inc. | Complement C3 precursor biopolymer markers indicative of insulin resistance |
| US7097989B2 (en) * | 2001-11-23 | 2006-08-29 | Syn X Pharma, Inc. | Complement C3 precursor biopolymer markers predictive of type II diabetes |
| JP2008502323A (ja) * | 2004-04-30 | 2008-01-31 | ユニバーシティ・オブ・ハワイ | コブラ毒因子様機能を有するヒト補体ｃ３誘導体 |
| US10206998B2 (en) | 2005-01-12 | 2019-02-19 | Proteonova, Inc. | Modular targeted therapeutic agents and methods of making same |
| WO2006076417A1 (en) * | 2005-01-12 | 2006-07-20 | Proteonova, Inc. | Method for making targeted therapeutic agents |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| RU2542401C1 (ru) * | 2013-11-06 | 2015-02-20 | Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ определения функциональной активности компонента с2 комплемента человека |
| RU2542404C1 (ru) * | 2013-11-06 | 2015-02-20 | Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ определения функциональной активности компонента с4 комплемента человека |
| US11903996B2 (en) * | 2015-10-07 | 2024-02-20 | David C. Fritzinger | Modulators of complement function |
| CN113214373B (zh) * | 2020-02-06 | 2022-08-30 | 深圳华大基因股份有限公司 | 新包虫病抗原Murinoglobulin-2蛋白 |
| US11918624B2 (en) * | 2020-06-10 | 2024-03-05 | Kelsius Laboratories LLC | Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4661347A (en) * | 1982-11-12 | 1987-04-28 | Scripps Clinic | Cytotoxic compositions |
-
1995
- 1995-09-08 BR BR9509172A patent/BR9509172A/pt not_active Application Discontinuation
- 1995-09-08 AU AU34772/95A patent/AU707004B2/en not_active Ceased
- 1995-09-08 CA CA002197888A patent/CA2197888A1/en not_active Abandoned
- 1995-09-08 CN CN95194984A patent/CN1104501C/zh not_active Expired - Fee Related
- 1995-09-08 WO PCT/GB1995/002121 patent/WO1996007738A2/en active IP Right Grant
- 1995-09-08 HU HU9800775A patent/HUT77874A/hu unknown
- 1995-09-08 AT AT95931276T patent/ATE273388T1/de not_active IP Right Cessation
- 1995-09-08 RO RO97-00417A patent/RO117189B1/ro unknown
- 1995-09-08 ES ES95931276T patent/ES2224133T3/es not_active Expired - Lifetime
- 1995-09-08 DE DE69533359T patent/DE69533359T2/de not_active Expired - Fee Related
- 1995-09-08 NZ NZ333949A patent/NZ333949A/en unknown
- 1995-09-08 NZ NZ292565A patent/NZ292565A/xx unknown
- 1995-09-08 SK SK296-97A patent/SK29697A3/sk unknown
- 1995-09-08 RU RU97105374/13A patent/RU2194713C2/ru not_active IP Right Cessation
- 1995-09-08 PL PL95319040A patent/PL319040A1/xx unknown
- 1995-09-08 JP JP8509319A patent/JPH10505241A/ja not_active Ceased
- 1995-09-08 EP EP95931276A patent/EP0779922B1/en not_active Expired - Lifetime
- 1995-09-08 CZ CZ1997685A patent/CZ290596B6/cs not_active IP Right Cessation
-
1997
- 1997-02-07 US US08/793,126 patent/US5849297A/en not_active Expired - Lifetime
- 1997-03-07 BG BG101295A patent/BG63606B1/bg unknown
- 1997-03-07 NO NO971059A patent/NO971059L/no unknown
- 1997-03-07 FI FI970979A patent/FI970979A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI970979A (fi) | 1997-03-07 |
| HUT77874A (hu) | 1998-09-28 |
| PL319040A1 (en) | 1997-07-21 |
| ATE273388T1 (de) | 2004-08-15 |
| EP0779922B1 (en) | 2004-08-11 |
| BG101295A (en) | 1997-12-30 |
| DE69533359T2 (de) | 2005-07-28 |
| AU3477295A (en) | 1996-03-27 |
| SK29697A3 (en) | 1998-01-14 |
| RU2194713C2 (ru) | 2002-12-20 |
| CA2197888A1 (en) | 1996-03-14 |
| BG63606B1 (bg) | 2002-06-28 |
| MX9701783A (es) | 1997-10-31 |
| AU707004B2 (en) | 1999-07-01 |
| CZ290596B6 (cs) | 2002-08-14 |
| NO971059D0 (no) | 1997-03-07 |
| NZ292565A (en) | 1999-03-29 |
| FI970979A0 (fi) | 1997-03-07 |
| CN1162335A (zh) | 1997-10-15 |
| NZ333949A (en) | 2000-06-23 |
| CN1104501C (zh) | 2003-04-02 |
| WO1996007738A2 (en) | 1996-03-14 |
| NO971059L (no) | 1997-05-07 |
| US5849297A (en) | 1998-12-15 |
| WO1996007738A3 (en) | 1996-03-28 |
| RO117189B1 (ro) | 2001-11-30 |
| ES2224133T3 (es) | 2005-03-01 |
| EP0779922A2 (en) | 1997-06-25 |
| DE69533359D1 (de) | 2004-09-16 |
| JPH10505241A (ja) | 1998-05-26 |
| CZ68597A3 (en) | 1997-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
| EA199800946A1 (ru) | Концентрированный препарат антител | |
| BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
| BR0008161A (pt) | Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral | |
| IL152886A0 (en) | B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same | |
| NO20000934D0 (no) | Adipocyttspesifikke proteinhomologer | |
| DE69535719D1 (de) | Fas-antigenbindender ligand | |
| DE69434384D1 (de) | Metalkomplexbildner | |
| DE3672950D1 (de) | Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung. | |
| BR9709958A (pt) | Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso | |
| DE69834643D1 (de) | Adipozyten-spezifische protein homologe | |
| ES2042461T1 (es) | Producto y procedimiento para el te\ido oxidativo del cabello. | |
| EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
| DK0707473T3 (da) | Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler | |
| ATE141415T1 (de) | Konjugate von antikörpern mit variablen domänen | |
| AR006150A1 (es) | Proteina de via complementaria natural modificada capaz de formar una convertasa c3 resistente a la regulacion descendente, secuencias de adn quecodifican dicha proteina, usos de dicha proteina y composiciones que la contienen | |
| PT723552E (pt) | Oligopeptidos derivados de fragmentos de proteina reactiva c | |
| DK0939769T3 (da) | Vertebrat-Smoothened-proteiner | |
| PT88913A (pt) | Processo para a preparacao da proteina pp4-x anticoagulante | |
| TR200002611T2 (tr) | Beta-lipotropin ve kullanımları | |
| AR005811A1 (es) | Proteina de via complementaria natural modificada, secuencia y construccion de adn que la codifica, conjugado y formulacion farmaceutica que la comprende,su uso y metodo para reducirla en un mamifero. | |
| ATE223227T1 (de) | Verwendung von lbp zur sepsistherapie | |
| DE69907727D1 (de) | Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen | |
| EA199900934A1 (ru) | Применение микрочастиц, содержащих адсорбированные на них белок и антитела, для получения фармацевтической композиции для интраназального введения | |
| BR1100801A (pt) | Proteìna, peptìdeo, proteìna ou peptìdeo, sequência de dna, processo para a preparação de uma proteìna ou peptìdeo, anticorpo, composição farmacêutica, e, uso de uma proteìna ou peptìdeo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C12N 9/64 (2006.01), A61K 47/68 (2017.0 |